BNET Industries
AstraZeneca Plc. is in the Pharma Industry
Latest News and Analysis
Attractively Valued International Dividend Stocks
Dobromir Stoyanov submits: Ever since the broad market indexes entered into bear market territory and the dollar stopped falling against most of the major currencies, I have been checking the international dividend achievers list for bargains. I came up with the following dividend stocks list, using the following screen criteria:...
AstraZeneca Begins Its Flu Campaign Season, and Pharma Donates to Candidates
Mike Huckman submits: Talk about timely direct-to-consumer advertising. Last week, I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political. To coincide with the official start of the presidential campaign season and the Democratic National...
Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising
Derek Lowe submits: Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, which has sat down to estimate how well various drug companies will do with revenue from new drugs...
AstraZeneca Gives FluMist Spray a Shot in the Arm
Mike Huckman submits: Ads for flu vaccines have traditionally been confined to public service announcements PSAs, health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New York Times last weekend for FluMist from AstraZeneca AZN/MedImmune. by Mike Huckman
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
Abbott Labs Beefs Up Its Drug Portfolio and Stent Business
Mike Huckman submits: The market cap of Dow component Johnson & Johnson JNJ is a whopping $200 billion. Abbott Labs ABT is valued at less than half that. But think of Abbott as a kind of mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a...
How Have 'Traditional Defensive Stocks' Done in This Downturn?
Larry Bellehumeur submits: Like many people on Seeking Alpha, I tend to watch a lot of Business-related programming on Bloomberg and BNN Canada. Over the past few months, more and more Analysts and Fund Managers are telling the viewers to “get more defensive” in their portfolio. When asked which...
How Not to Do An Acquisition: AstraZeneca-MedImmune
When AstraZeneca ponied up more than $15 billion for the biotech MedImmune just over a year ago, the deal suggested that desperate Big Pharmas were willing to open their wallets wide for biotechs without looking too closely into the question of whether they were really worth the money. As I...
Swedish IT company Sigma AB receives contract expansion from AstraZeneca
NORDIC BUSINESS REPORT-12 June 2008-Swedish IT company Sigma AB receives contract expansion from AstraZenecaC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com
Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
GOTHENBURG, Sweden, June 11 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput platform, DynaflowRHT, for ion channel screening.
Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD
WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics TM, today announced the initiation of a Phase 2 clinical trial of AZD3480 (TC-1734) in adults with Attention Deficit/Hyperactivity Disorder, or ADHD.
WuXi PharmaTech Expands Collaboration With AstraZeneca
SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech , a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration agreement with AstraZeneca.
AstraZeneca Submits an sNDA for SYMBICORT® for the Treatment of Asthma in Children as Young as Age Six
WILMINGTON, Del., June 4 /PRNewswire-FirstCall/ -- AstraZeneca today announced that it submitted a supplemental New Drug Application sNDA to the U.S. Food and Drug Administration FDA for approval of a new indication for SYMBICORTR (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in pediatric...
AstraZeneca Receives Award for Pioneering Use of SAFE-BioPharma Digital Signatures to Sign Electronic Submissions to FDA
FT. LEE, N.J. -- AstraZeneca Pharmaceuticals AZ has received Bio-IT World magazine's 2008 Best Practices Grand Prize for its pioneering use of SAFE-BioPharma[TM] digital signatures to sign electronic submissions made through the FDA's eSubmissions Gateway.
Protherics Plc Announces Final Results
PROTHERICS ANNOUNCES PRELIMINARY RESULTS FOR YEAR ENDED 31 MARCH 2008 Strong increase in underlying revenues and robust financial position Solid progress across...
Phase III Study of Abbott's Investigational TriLipix™ in Combination With AstraZeneca's CRESTOR® Meets Primary Endpoints on Key Lipids
Data Show TriLipix (ABT-335) in Combination with CRESTOR rosuvastatin calcium Improved LDL, HDL and Triglycerides and Had Reported Safety Consistent with Monotherapies
Swedish speciality pharma company BioPhausia AB acquires drug portfolio from AstraZeneca
NORDIC BUSINESS REPORT-26 May 2008-Swedish speciality pharma company BioPhausia AB acquires drug portfolio from AstraZenecaC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com
Research and Markets: Authoritative Insight into AstraZeneca at a Strategic and Local Level
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c92277) has announced the addition of "AstraZeneca IMS Company Profile" to their offering.
Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources
FDA Approves AstraZeneca's Seroquel® for Maintenance Treatment in Bipolar Disorder
WILMINGTON, Del., May 14 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the U.S. Food and Drug Administration FDA has approved SEROQUELR quetiapine fumarate tablets for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex. SEROQUEL is approved by the FDA for the...
- Next »
- page 1 of 31
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- FDA (34 results)
- Pfizer Inc. (15 results)
- Sales (15 results)
- Novartis AG (13 results)
- collaboration (13 results)
- pharmaceutical company (11 results)
- agreement (11 results)
- GlaxoSmithKline Plc. (11 results)
- Bristol-Myers Squibb Co. (10 results)
- New York Stock Exchange (10 results)
- patient (10 results)
- Company (10 results)
- Daily Mail (10 results)
- Sanofi-Aventis (9 results)
- Merck & Co. Inc. (9 results)
- R&D (9 results)
- health care (9 results)
- blog (9 results)
- Eli Lilly & Co. (8 results)
- partnership (8 results)
- Merger (7 results)
- Finance (7 results)
- stock (7 results)
- life science (7 results)
- Acquisition (6 results)
- Cell (6 results)
- marketing (6 results)
- Strategy (5 results)
- MedImmune Inc. (5 results)
- breast cancer (5 results)
- Johnson & Johnson (5 results)
- patent (5 results)
- Procter & Gamble Co. (5 results)
- Siebel Systems Inc. (4 results)
- class action (4 results)
- Wyeth (4 results)
- tablet (4 results)
- Schering-Plough Corp. (4 results)
- asthma (4 results)
- European Commission (4 results)
- industry (4 results)
- Healthcare (4 results)
- job (4 results)
- Biogen Idec Inc. (3 results)
- RANBAXY (3 results)
- IMS Health Inc. (3 results)
- Abbott Laboratories Inc. (3 results)
- Clear (3 results)
- team (3 results)
- alliance (3 results)
AstraZeneca Plc. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
